Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study
BackgroundProton pump inhibitors (PPIs) are the most effective antacids and are widely used in the treatment of acid-related diseases. However, the impact of PPIs on bone remains controversial. This study aimed to explore the association between PPIs and osteoporosis-related adverse events in the re...
Saved in:
| Main Authors: | Jingkai Di, Nan Yang, Yicong Zhao, Shuai Chen, Zijian Guo, Dongdong He, Chuan Xiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1582908/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Thrombotic adverse events associated with TNF-alpha blockers: a real-world pharmacovigilance analysis of the FAERS database
by: Lijuan Song, et al.
Published: (2025-04-01) -
An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis
by: Jingkai Di, et al.
Published: (2025-07-01) -
METHOTREXATE AND PROTON PUMP INHIBITORS: ARE THERE ANY NEGATIVE PHARMACOLOGIAL EFFECTS?
by: Andrey E Karateev, et al.
Published: (2014-02-01) -
Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database
by: Lu Liu, et al.
Published: (2025-07-01) -
Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database
by: Xiang Li, et al.
Published: (2025-04-01)